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Fast and efficient
genetic engineering of
hematopoietic
precursor cells for the
study of dendritic cell
migration
Dendritic cells (DCs) are sentinels of
the adaptive immune system that reside
in peripheral organs of mammals. Upon
pathogen encounter, they undergo mat-
uration and up-regulate the chemokine
receptor CCR7 that guides them along gra-
dients of its chemokine ligands CCL19 and
21 to the next draining lymph node. There,
DCs present peripherally acquired antigen
to na¨ıve T cells, thereby triggering adap-
tive immunity [1, 2]. Their high migratory
speed and chemotactic prowess, the rela-
tive ease to generate large cell numbers in
culture and their suitability for in vitro and
in vivo assays has made DCs one of the
most powerful tools to study cell migra-
tion [3]. Typically, DCs are differentiated
fromun-fractionated bonemarrow (BM) in
the presence of differentiation-promoting
factors such as granulocyte-macrophage
colony stimulating factor (GM-CSF) [4].
Once mature, these terminally differenti-
ated BM DCs have a very limited lifes-
pan, impeding stable genetic modifica-
tions. Consequently, research is hampered
by time- and resource-consuming genera-
tion of genetic mouse models.
To overcome these limitations, several
methods have been developed to obtain
long-term DC cultures. This has been
either achieved by differentiation of DCs
from embryoid bodies [5], oncoprotein
driven immortalization of DCs [6–9], or
growth factor dependent, long-term cul-
ture of splenic DCs [10]. Although migra-
tory properties are considered to be one
of the hallmarks of DC biology, we never
observed efficient migration in any of these
cultures (personal observation).
Recently, Flt3L expanded hematopoi-
etic precursors, transiently immortalized
via a retrovirally delivered, estrogen
inducible form of the transcription factor
Hoxb8 have been introduced (Hoxb8-FL
cells) [11]. Upon estrogen withdrawal and
GM-CSF culture the resulting DCs closely
resemble BM DCs in their transcriptome,
cytokine secretion and priming of na¨ıve T
cells (Fig. 1A) [11].
For direct comparison we differentiated
DCs from BM and Hoxb8-FL cells side-
by-side in the presence of GM-CSF [4].
Cells from both origins expressed high lev-
els of the DC markers Cd11c and major
histocompatibility complex II (MHCII, Fig.
1B). Importantly, Hoxb8-FL DCs expressed
CCR7 [2], albeit at slightly lower lev-
els as compared to BM DCs (Fig. 1B).
When incorporated into 3D collagen gels
[12] and recorded by time-lapse video
microscopy both fractions showed vivid
protrusion dynamics and migrated per-
sistently for several micrometers before
rounding up and changing direction (Sup-
porting Information Movie 1). Migratory
speeds of Hoxb8-FL DCs were slightly
reduced as compared to BM DCs (Fig.
1C). When exposed to gradients of CCL19,
HoxB8-FL DCs showed a strong chemotac-
tic response with a slightly reduced chemo-
tactic index compared to BM DCs, poten-
tially attributable to lower levels of CCR7
(Fig. 1D and E and Supporting Informa-
tion Movie 1). Finally, we co-injected dif-
ferently labeled DCs of both origins into
mouse footpads and found that they arrive
in comparable numbers in the popliteal
lymph node 24 h after injection (Fig. 1F).
Taken together, Hoxb8-FL DCs showed
robust migratory behavior and chemotaxis
in vitro and in vivo.
Next, we set out to probe the tractabil-
ity for genetic modifications via the
CRISPR/Cas9 system. As a proof of prin-
ciple, we first assessed if a fluorescent
reporter (GFP) could be deleted in undif-
ferentiated Hoxb8-FL cells. Hoxb8-FL cells,
homozygous for membrane GFP (mG),
were infected with lentiviruses coding
for puromycin resistance, Cas9 and a
guide RNA (gRNA) [13] directed against
GFP (anti-GFP-1 or 2) or a scrambled
(scrbl) control. GFP negative cells could be
detected 3 to 4 days after infection while
negligible signal was detected in the GFP
negative gate of scrbl infected cells (Fig.
1G). To determine the efficiency of the
CRISPR/Cas9 system in Hoxb8-FL cells,
we exposed infected mG cells to antibi-
otic selection and expanded survivors. We
found that more than 90% of mG cells
infected with gRNA anti- GFP-1 were GFP
negative. For gRNA anti-GFP-2 this effect
was even stronger, with almost 100% of
cells in the GFP negative gate. In con-
trast, mG cells infected with the scrbl
gRNA lentivirus retained their fluorescence
(Fig. 1H). These results demonstrate that
CRISPR/Cas9 mediated genome editing in
HoxB8-FL progenitors is highly efficient.
Next, we wanted to explore if activity
of the CRISPR/Cas9 system interferes with
the ability of Hoxb8-FL cells to differenti-
ate to DCs and if endogenous genes can
be targeted with comparable efficiency.
Initially, we focused on the gene Itgb2,
coding for the leukocyte specific integrin
beta 2. Together with integrin alpha x
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Figure 1. Migratory properties of BM- and Hoxb8-FL DCs in vitro and in vivo. (A) Schematic of generation, maintenance, LentiCRISPR infection
and differentiation to DCs of Hoxb8-FL cells (B) FACS staining of DCs for Cd11c, MHCII and CCR7. CCR7 levels are pre-gated on Cd11c/MHCII high
population (gray boxes). (C) Mean single cell speeds (μm/min.) of DCs migrating in 3D collagen gels in presence or absence of CCL19 gradient. Mean
(red line) ± SD (black bars). Kruskal–Wallis test, ****p < 0.0001, n = 663/567 (BM-/Hoxb8 DCs CCL19), n = 235/299 (BM-/Hoxb8 DCs no chemokine),
pooled from three biologically independent experiments. (D) Mean single cell chemotactic indices of cells in (C). Kruskal–Wallis test, **p < 0.01. (E)
Average y-displacement (μm/min.) over time (min.) of BM- andHoxb8-FL DCs in the presence (circles) or absence (triangles) of CCL19 gradient. Mean
(dots/triangles) ± SEM (black bars). n = 6 collagen gels (CCL19) or n = 3 collagen gels (no chemokine), pooled from three biologically independent
experiments. (F) left: gating strategy to calculate the ratio of DCs in the draining lymph node 24 h after injection shown on the right. SD (black bars).
unpaired t-test, not significant, p = 0.3415. n = 6 (BM/BM) or n = 17 (Hoxb8/BM), pooled from two biologically independent experiments. (G) eGFP
expression levels of mG Hoxb8-FL cells 3 or 4 days after infection with indicated lentiviruses. (H) eGFP expression levels of mG or ctrl Hoxb8-FL
cells after infection with indicated lentiviruses and antibiotic selection.
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Figure 2. Characterization of Hoxb8-FL Itgb2 and ccr7 knockout DCs. (A) FACS staining of putative Itgb2 knockout DCs for Cd11c and MHCII. (B)
Cell area (pixel2) of putative Itgb2 knockout DCs, plated on CCL21. Mean (red line) ± SD (black bars). ANOVA, ****p < 0.0001. n = 10 cells from
each batch. (C) Snapshots of putative Itgb2 knockout DCs plated on CCL21. (D) FACS staining of putative ccr7 knockout DCs for Cd11c, MHCII and
CCR7. CCR7 levels are pre-gated on Cd11c/MHCII high population (black boxes). (E) Mean single cell speeds (μm/min.) of putative ccr7 knockout
DCs migrating in 3D collagen gels in CCL19 gradient. Mean (red line) ± SD (black bars). Kruskal–Wallis test, ****p < 0.0001, n = 755/421/406/574/256
(scrbl/anti-CCR7- 1/2/3/scrbl no chemokine), pooled from three biologically independent experiments. (F) Mean single cell chemotactic indices of
cells in (E). Kruskal–Wallis test, ****p < 0.0001. (G) Average y-displacement (μm/min.) over time (min.) of putative ccr7 knockout DCs in the presence
(circles) or absence (triangles) of CCL19 gradient. Mean (dots/triangles) ± SEM (black bars). n = 3 collagen gels (CCL19) or n = 2 collagen gels (scrbl,
no chemokine), pooled from three biologically independent experiments.
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WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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it forms the trans-membrane heterodimer
DC marker Cd11c. Beta 2 integrins medi-
ate cell-substrate adhesions and couple the
contractile force of the cytoskeleton to the
environment [14]. We designed three dif-
ferent gRNAs (anti-Itgb2- 1–3) directed
against Itgb2, produced lentiviruses and
infected HoxB8-FL cells. After antibiotic
selection, cells were expanded and dif-
ferentiated to DCs. Putative Itgb2 knock-
out and control cells were morphologi-
cally indistinguishable in suspension (data
not shown) and cells infected with the
scrbl gRNA showed high Cd11c and MHCII
levels (Fig. 2A). DCs derived from cells
infected with anti-Itgb2 showed no Cd11c
staining, while retaining high MHCII levels
(Fig. 2A). To obtain a functional read-out
we coated glass-slides with CCL21, which
triggers integrin beta 2 dependent adhe-
sion, polarization and migration trough
CCR7 [15]. DCs derived from anti-Itgb2
Hoxb8-FL cells failed to adhere to CCL21
coated glass slides (Fig. 2B and C and Sup-
porting Information Movie 2).
As a second endogenous candidate
we chose chemokine receptor CCR7. We
designed three, ccr7 specific- (anti-ccr7)
and one scrambled control gRNA. As in the
above-described experiments we observed
a relatively low number of infected Hoxb8-
FL cells surviving puromycin selection,
we compared blasticidin as an antibiotic
marker and found that survival rates are
increased (data not shown). DCs from
all infections showed normal Cd11c and
MHCII levels (Fig. 2D). Importantly, cells
from all anti-ccr7 infections showed a drop
in their CCR7 levels. In case of anti-ccr7-
2 and 3, it was almost reduced to iso-
type control levels, suggesting near com-
plete knockouts (Fig. 2D). In 3D colla-
gen gels DCs derived from anti-ccr7 infec-
tions showed a significantly lower mean
speed and entirely failed to migrate toward
a CCL19 source (Fig. 2E–G and Support-
ing Information Movie 3) as would be
expected for CCR7 knockouts that are
unresponsive to CCL19.
Taken together, we demonstrate that
knockouts can be easily and efficiently gen-
erated in Hoxb8-FL cells. These cells can be
further differentiated to DCs that behave
very similar to their BM derived coun-
terparts. Recently, it has been observed
that BM GM-CSF cultures, under cer-
tain culture conditions, comprise a het-
erogeneous population of macrophages
and DCs, both expressing Cd11c and
different levels of MHCII [16]. In our
hands GM-CSF cultures from both BM and
Hoxb8 origin, express homogenous lev-
els of MHCII and CCR7 (which is not
expressed by macrophages [16]) and thus
show a homogenous and complete chemo-
tactic response pattern. Genome editing
efficiency was high in our hands, although
for some gRNAs a certain small percent-
age of cells retained detectable protein.
Residual expression can be easily circum-
vented by, as shown here, designing multi-
ple gRNAs or by single cell cloning that will
also facilitate thorough characterization of
the genetic changes. The high efficiency
of CRISPR/Cas9 mediated gene knockouts
might also allow for infections of Hoxb8-FL
cells with pooled gRNA libraries for spe-
cific subsets of genes, followed by func-
tional screens. To gain complete control
over the Hoxb8-FL genome we are cur-
rently establishing knock-in strategies to
tag, replace andmutate endogenous genes.
This is ideally done with non-integrating
vectors, which is challenging due to the rel-
ative resistance of Hoxb8-FL cells to tran-
sient transfection. Notably, the potential of
Hoxb8-FL cells to differentiate into other
cell types of the myeloid and lymphoid lin-
eage (e.g. Flt3 DCs, macrophages, B cells
and T cells [11]) allows broader utilization
of the targeted precursor cells.
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